Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward Copelan

Showing results (71-80 of 87) with videos related to

Pageof 9
Sort By:
Blood Advances|October 2, 2020
Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDSVikas Gupta, Soyoung Kim, Zhen-Huan Hu, et al.
Blood|July 5, 2017
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United StatesLori Muffly, Marcelo C Pasquini, Michael Martens, et al.
Transplantation and Cellular Therapy|August 17, 2021
Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic SyndromesBetül Oran, Kwang Woo Ahn, Caitrin Fretham, et al.
Transplantation and Cellular Therapy|October 3, 2020
Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research StudyNelli Bejanyan, Meijie Zhang, Khalid Bo-Subait, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 12, 2020
A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic SyndromesAziz Nazha, Zhen-Huan Hu, Tao Wang, et al.
Blood Advances|May 13, 2020
Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseasesJustine M Kahn, Ruta Brazauskas, Heather R Tecca, et al.
Bone Marrow Transplantation|March 17, 2022
Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysisAntonio M Jimenez Jimenez, Marcos De Lima, Krishna V Komanduri, et al.
Bone Marrow Transplantation|September 29, 2021
An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysisAntonio M Jimenez Jimenez, Marcos De Lima, Krishna V Komanduri, et al.
Bone Marrow Transplantation|May 21, 2021
Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantationMary-Elizabeth Percival, Hai-Lin Wang, Mei-Jie Zhang, et al.
Bone Marrow Transplantation|April 17, 2021
Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantationMary-Elizabeth Percival, Hai-Lin Wang, Mei-Jie Zhang, et al.
Pageof 9

Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
Blood Advances|October 2, 2020
Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDSVikas Gupta, Soyoung Kim, Zhen-Huan Hu, et al.
Blood|July 5, 2017
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United StatesLori Muffly, Marcelo C Pasquini, Michael Martens, et al.
Transplantation and Cellular Therapy|August 17, 2021
Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic SyndromesBetül Oran, Kwang Woo Ahn, Caitrin Fretham, et al.
Transplantation and Cellular Therapy|October 3, 2020
Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research StudyNelli Bejanyan, Meijie Zhang, Khalid Bo-Subait, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 12, 2020
A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic SyndromesAziz Nazha, Zhen-Huan Hu, Tao Wang, et al.
Blood Advances|May 13, 2020
Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseasesJustine M Kahn, Ruta Brazauskas, Heather R Tecca, et al.
Bone Marrow Transplantation|March 17, 2022
Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysisAntonio M Jimenez Jimenez, Marcos De Lima, Krishna V Komanduri, et al.
Bone Marrow Transplantation|September 29, 2021
An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysisAntonio M Jimenez Jimenez, Marcos De Lima, Krishna V Komanduri, et al.
Bone Marrow Transplantation|May 21, 2021
Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantationMary-Elizabeth Percival, Hai-Lin Wang, Mei-Jie Zhang, et al.
Bone Marrow Transplantation|April 17, 2021
Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantationMary-Elizabeth Percival, Hai-Lin Wang, Mei-Jie Zhang, et al.
Pageof 9